BIM-23190 

BIM-23190, a somatostatin analog, a selective SSTR2 and SSTR5 agonist, exhibits K_i values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly^[1][3].

BIM-23190 tends to mildly stimulate PRL secretion^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

BIM-23190 (50 μg/mouse, twice a day) exhibits significant anti-tumor (C6 glioma) activity^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1202.45

C₅₇H₇₉N₁₃O₁₂S₂

182153-96-4

{4-(2-Hydroxyethyl)-1-piperazinylacetyl}-{D-Phe}-Cys-Tyr-{D-Trp}-Lys-{Abu}-Cys-Thr-NH2 (Disulfide bridge: Cys2-Cys7)

{4-(2-Hydroxyethyl)-1-piperazinylacetyl}-{D-Phe}-CY-{D-Trp}-K-{Abu}-CT-NH2 (Disulfide bridge: Cys2-Cys7)

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. I Shimon, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest. 1997 Nov 1;100(9):2386-92.  [Content Brief]

  [2]. Federica Barbieri, et al. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1078-88.  [Content Brief]

  [3]. T J Gillespie, et al. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. J Pharmacol Exp Ther. 1998 Apr;285(1):95-104.  [Content Brief]